HIV-1 Treatment and Pre-Exposure Prophylaxis
Research activity centers on oral maintenance and switching regimens for virologically suppressed people with HIV-1 infection, treatment-naive populations, and prevention strategies for individuals at risk of acquisition. The portfolio also includes pediatric and adolescent studies, reflecting interest across age groups and clinical settings.
- Virologically suppressed people with HIV-1
- Pre-exposure prophylaxis
- Pediatric and adolescent HIV care
- Antiretroviral switching strategies
Key areas include lenacapavir, islatravir, bictegravir, emtricitabine, tenofovir alafenamide, and combination regimens designed to support long-term HIV management.
Viral Hepatitis and Liver Disease
The sponsor funds studies in chronic hepatitis B and chronic hepatitis D, including research in adults, adolescents, and children. Additional work addresses liver-related outcomes in chronic viral hepatitis and progressive hepatic disease.
- Chronic hepatitis B
- Chronic hepatitis D infection
- Liver disease progression
- Pediatric hepatitis management
Therapeutic interest also extends to tenofovir-based approaches, bulevirtide, and investigational agents for hepatitis-associated liver complications.
Oncology and Solid Tumor Therapy
Clinical research spans multiple cancer types, with emphasis on metastatic solid tumors, non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer, urothelial cancer, colorectal cancer, and head and neck squamous cell carcinoma. The portfolio also includes endometrial cancer, gastric cancer, and other advanced malignancies.
- Metastatic solid tumors
- Non-small cell lung cancer
- Triple-negative breast cancer
- Urothelial cancer
- Colorectal and head and neck cancers
Investigational work includes sacituzumab govitecan and immunotherapy-based combinations, alongside studies in PD-L1-positive disease and other biomarker-defined cancer populations.
Inflammatory, Autoimmune, and Cholestatic Liver Disorders
Trials also address immune-mediated and hepatobiliary conditions, including primary biliary cholangitis, ulcerative colitis, rheumatoid arthritis, and cutaneous lupus erythematosus. These studies cover both systemic and organ-specific inflammatory disease.
- Primary biliary cholangitis
- Ulcerative colitis
- Rheumatoid arthritis
- Cutaneous lupus erythematosus
Research interest includes seladelpar, GS-5290, GS-5718, and other agents targeting inflammatory activity and liver-related symptoms.
Respiratory, Viral Infection, and Renal Impairment
Additional studies cover COVID-19, advanced non-small cell lung cancer, and pharmacokinetic evaluation in renal impairment. This area reflects interest in infectious disease, respiratory oncology, and treatment considerations in reduced kidney function.
- COVID-19
- Renal impairment
- Respiratory oncology
- Antiviral therapeutics
Studies include obeldesivir in pediatric COVID-19 and renal-function-focused assessment of antiviral exposure.
